Key statistics dashboard for Alector, Inc. (ALEC). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders.
Stock Data
| Price | $1.93 |
| Market Cap | $214M |
| Beta | 0.58 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -1.80 |
| Price / Book | -22.14 |
| P/S | 15.90 |
| P/FCF | -1.39 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | -360.92% |
| EBIT Margin | -847.98% |
| EBITDA Margin | -777.92% |
| Operating Margin | -914.56% |
| Net Margin | -850.13% |
Financial Health
| Current Ratio | 5.26 |
| Quick Ratio | 5.26 |
| Cash Ratio | 1.75 |
| Debt / Equity | -3.29 |
| Debt / Assets | 16.15% |
| Interest Coverage | 0.00 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -5.04 |
Per-Share Data
| Revenue per share | 0.12 |
| Book Value per share | -0.09 |
| Cash per share | 1.55 |
| FCF per share | -1.42 |
| Tangible Book Value per share | -0.09 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 9 |
| Hold | 3 |
| Sell | 2 |
| Strong Sell | 0 |
| Total analysts | 14 |
| Avg rating (1-5) | 0.50 |
Related companies: ABOS · APLT · CRBP · FATE · IRD · MOLN · NKTX
Explore sector: Healthcare · Biotechnology
More sections of ALEC: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks